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Abstract. In this work we explored the role of the 3’UTR of the MECP2 gene in patients with clinical diagnosis of RTT and
mental retardation; focusing on regions of the 3’UTR with almost 100% conservation at the nucleotide level among mouse and
human. By mutation scanning (DOVAM-S technique) the MECP2 3’UTR of a total of 66 affected females were studied. Five
3’UTR variants in the MECP2 were found (c.1461+9G>A, c.1461+98insA, c.2595G>A, c.9961C>G and c.9964delC) in our
group of patients. None of the variants found is located in putative protein-binding sites nor predicted to have a pathogenic role.
Our data suggest that mutations in this region do not account for a large proportion of the RTT cases without a genetic explanation.
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1. Introduction
Mutations in the MECP2 gene are associated with
Rett syndrome (RTT, OMIM # 312750) [1], a disor-
der affecting mainly females, presenting with mental
retardation, autistic features and a movement disorder.
The disease is characterized by an apparently initial
normal developmental period, followed by a reduction
in growth and loss of motor and cognitive skills around
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the age of 6 to 18 months [15,16]. Mutations in the
coding region of MECP2 are identified in around 80–
90% of classical RTT patients (presenting the above
described phenotype), and 30% of variant forms of the
disease, which includes more severe presentations such
as neonatal encephalopathy and milder presentations
such as the preserved speech variant or forme fruste [16,
19]. Thus, the cause of disease in a significant pro-
portion of patients with RTT remains unknown. It has
been proposed that mutations in non-coding regions of
MECP2, untranslated regions (5’ and 3’UTR) and in-
trons, or in other genes may be the unidentified cause
of the disorder in these cases.
The role of the 3’UTR of a gene might be the regu-
lation of its expression at different levels, such as the
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“translatability” of an mRNA, its stability, nuclear ex-
port or the sub-cellular localization of the translation
event, thus affecting the levels of the resulting protein
(for a review see [7]). The latter mechanisms have been
demonstrated in neurons for the immediate-early gene
Arc (apoptosis repressor with CARD) and the protein
αCamKII (calcium/calmodulin-dependent protein ki-
nase II-alpha) which are translated locally at/near the
synapse [5].
Additionally, the 3’UTR of the CamKII gene has
been linked to the regulation of activity-dependent
CamKII protein expression, via glutamate N-methyl-
D-aspartate glutamate receptor (NMDAR) activation.
This regulation is on the basis of synaptic plasticity,
learning and memory formation [28], all of which are
disturbed in RTT.
A study based on the human gene mutation database
(HGMD) estimated that around 0.2% of the disease-
associated mutations reside in the regulatory regions
of the 3’UTR of genes [6]. Mutations in the 3’UTR
have been identified as the genetic cause of a num-
ber of diseases with a neurological component: (1)
myotonic dystrophy, a neuromuscular disorder char-
acterized by hypotonia, mental retardation and mus-
cle development defects, due to a CTG repeat expan-
sion in the 3’UTR of the dystrophia myotonica pro-
tein kinase gene (DMPK) [12]; (2) IPEX syndrome
(immune dysfunction, polyendocrinopathy, enteropa-
thy, X-linked), caused by a mutation within the first
polyadenylation signal of the forkhead box P3 gene
(FOXP3) [3]; (3) Fukuyama-type congenital muscular
dystrophy, presenting with mental retardation and brain
defects, caused by a defect in the Fukutin gene [17]
and (4) familial Danish dementia, caused by a decamer
duplication in the integral membrane protein 2B gene
(BRI) [25]; finally, (5) a nucleotide change found in
the 3’ regulatory region of the cyclin-dependent kinase
5, regulatory subunit 1 gene (CDK5R1), was also sug-
gested to be a cause of non-syndromic mental retarda-
tion [24]. The mechanisms involved are variable and
these mutations cause pathology either by affecting (1)
the splicing of other genes as in the case of myotonic
dystrophy [20], (2) the mRNA maturation as is the case
in IPEX syndrome [2], (3) the mRNA stability as in the
case of Fukuyama-type congenital dystrophy [17] or
the expression levels as it happens in familiar Danish
dementia [25]. However, other variants at the 3’UTR
of other genes were not found to be associated with dis-
ease, as is the case of the CAA insertion polymorphism
in the NOGO gene in schizophrenia and bipolar disor-
der [14] and the B7-1 gene in patients with multiple
sclerosis [27] among many others.
The MECP2 gene has eight different transcripts that
result from alternative splicing and different sites of
polyadenylation and one of the longest known 3’UTR
tails, with 8.5-kb [9]. The longest transcript is more
than 10 kb long and has several blocks of highly
conserved residues between the human and mouse
genomes (Fig. 1). This argues in favour of a poten-
tial regulatory role of this 3’UTR in the function of
the MeCP2 protein, in different cell types and at dif-
ferent developmental times. The longest transcript is
also generally described as the predominant form in the
brain [9,10,21].
In this work we explored the potential role of the ex-
tremely large and conserved 3’UTR of the MECP2 gene
in patients with clinical diagnosis of RTT and mental
retardation: we performed a bioinformatics analysis in
order to identify putative protein-binding sites and we
searched for mutations in selected regions of this 3’
UTR, highly conserved among mouse and human, in
an attempt to identify sequence variations leading to
disease.
2. Subjects and methods
2.1. Bioinformatics
We used the ESResearch program (http://ast.bioinfo.
tau.ac.il/ESR.htm) to search the MECP2 3’UTR for po-
tential binding sites of RNA-binding proteins [11,13,
26,29] and the BLAST program (http://www.ncbi.nlm.
nih.gov/BLAST/) to identify regions at high conserva-
tion between human and mouse MECP2 3’UTR.
2.2. Subjects
We have included in the study a total of 66 affected
females who had already been studied for MECP2 mu-
tations in its coding region and exon-intron boundaries,
including detection of large rearrangements by robust
dosage-PCR method (33 were positive for MECP2 mu-
tations in the coding region of the gene), 51 with a
clinical diagnosis of RTT, 35 classical and 16 atypical,
according to the reviewed criteria of Hagberg and col-
leagues [15,16], 13 with mental retardation with autism
and 2 with an Angelman syndrome-like clinical pre-
sentation. Whenever possible, both parents were also
included in the study. A control population of 40 males
and 83 females was used in order to characterize the
frequency of the new variants found. All participants
or their legal representatives gave informed consent
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Fig. 1. Schematic representation of MECP2 gene with the 3’UTR sequence variants identified. Grey boxes, exons 1 to 4; black boxes, 5’ and
3’UTR; grey bars, regions scanned by DOVAM-S.
for this study. The study conforms with The Code of
Ethics of the World Medical Association (Declaration
of Helsinki) and was reviewed and approved by the re-
search ethics committee of the Life and Health Sciences
Research Institute.
2.3. Molecular analysis of the MECP2 3’UTR
Genomic DNA was extracted from the peripheral
blood of the patients and available parents using the
Puregene DNA extraction system (Gentra).
Selection of the non-coding regions of the MECP2
3’UTR to be analysed was performed based on
conservation among species (86%–98% conserva-
tion at the nucleotide level), in a total of 9 blocks
(NM 004992: c.1607–c.1956, c.2561–c.2891, c.3551–
c.3805, c.3768–c.4128,c.6851–c.7029,c.7116–c.7436,
c.8372–c.8645, c.8607–c.8872 and c.9844–c.10182.
These 9 blocks of conservation include three of the
four polyadenylation signals and their nearby regulato-
ry regions of the MECP2 gene (∼ 1.8, ∼ 7 and ∼ 10)
(Fig. 1).
The 3’UTR blocks were scanned for mutations
with the Detection Of Virtually All Mutations-SSCP
(DOVAM-S) technique [18,23]. The different DNA
segments were first amplified robotically, pooled, de-
natured and electrophoresed under five nondenatur-
ing conditions varying in gel matrix, buffer, tem-
perature, and additive: (1) 10% PAGE+/30 mM
Tricine/Triethanolamine at 20◦C, (2) 10% HR1000/
30 mM Tricine/Triethanolamine at 4◦C, (3) 10%
PAGE+/TBE/5% glycerol at 20◦C, (4) 10% HR1000/
TBE/2.5% glycerol at 4◦C, (5) 10% PAGE+/30 mM
Capso at 4◦C. PCR products with mobility shifts were
sequenced with the ABI model 377 (Perkin-Elmer
Model 377, Norwalk, CT) and nucleotide alterations
were analyzed. Sequence changes were confirmed by
re-amplification of genomic DNA and sequencing in
the opposite direction. The primers used for amplifi-
cation of the 3’UTR of MECP2 as well as the PCR
conditions used, are listed in Table 1.
For the DNA amplification of the different 3’UTR
blocks, a final volume of 25 µl PCR mixture (2.5 mM
MgCl2, 0.2 mM dNTP, 2.5 µM of each primer and 2U
of AmpliTaq Gold (Applied Biosystems)) was used.
The thermal cycling profile consisted of an initial de-
naturation for 10 min at 94◦C, 35 cycles of a denatura-
tion for 15 sec at 94◦C, annealing for 30 sec at 55 ◦C,
extension for 1 min at 72◦C, and a final extension for
10 min at 72◦C.
2.4. Allele specific-PCR (AS-PCR)
The presence of the MECP2 3’UTR variants
c.2595G>A and c.9961C>G was tested in a control
population by AS-PCR. The primers used for allele spe-
cific amplification of the MECP2 3’UTR variants, as
well as the PCR conditions used, are listed in Table 1.
Two PCR mixtures for each variant were prepared
in order to amplify either the normal or the mutated
allele, in a final volume of 25 µl PCR mixture that
consisted of 0.5 mM MgCl2, 0.2 mM dNTP, 0.8 µM
of each primer pair (either for the normal allele or for
the mutated allele) and 1.5 U of Taq DNA polymerase
(Fermentas). The thermal cycling profile consisted of
an initial denaturation for 5 min at 95◦C, 35 cycles
of a denaturation for 1 min at 95◦C, annealing for 1
min at Ta ◦C (specific for each variant, see Table 1),
extension for 1 min at 72◦C, and a final extension for
5 min at 72◦C. PCR products were electrophoresed in
a 2% agarose gel, and visualized under UV light.
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Table 1
Primer pairs and their sequences, PCR segments size and Ta used in PCR, AS-PCR and sequencing of the 3’UTR of MECP2
Gene Region NM 004992 Primer Sequence (5’>3’) Size (bp) Tm (◦C) Ta (◦C)
MECP2 3’UTR 1607–1956 MD14 CGTGACCGAGAGAGTTAGC 350 60 55
MU14 CGGGAGGGGAGGTGCC 58
2561–2891 MD15 CCAGTTACTTTCCAATTCTCC 331 58 55
MU15 AGAAGTGAAAGGATGAAATGAA 58
3551–3805 MD16 GCTTAGAGGCATGGGCTTG 255 60 55
MU16 CAGCAGCTCACATGGGACA 60
3768–4128 MD17 CCAGAAACACCCACAGGCA 361 60 55
MU17 TTGGGCTGATGGGAGTTTG 58
6851–7029 MD18 GCAGATGAGGTGAAAAGGC 179 58 55
MU18 GCAAAACAAAAGCCCAGGAT 58
7116–7436 MD19 CTGTATATTGCACAATTATAAAC 321 58 55
MU19 ACCCAGAACCTTGGGACC 58
8372–8645 MD20 GGAGTGCAAAAGGCTTGCA 274 58 55
MU20 GAAAAACCCCAGAAAGACAAG 60
8607–8872 MD21 TTCCTTCTTTGCCCTTTACTTGTC 266 58 55
MU21 GTAAAGAAAAAGTGTCTAGAAAT 58
9844–10182 MD22 GGCCGGGACACACTTAGC 339 60 55
MU22 AAATTTATAAGGCAAACTCTTTAT 58
MECP2 variant
c.2595G>A 2595G>An F GCGCTTGTTTTAAAGTGGG 148 56 59
2595G>Am F GCGCTTGTTTTAAAGTGGA 54
MU15 AGAAGTGAAAGGATGAAATGAA 58
c.9961C>G 9961C>Gn F ACGTTTCAAAAACACCCCCCC 161 64 61
9961C>Gm F ACGTTTCAAAAACACCCCCCC 64
MU23 CTGCCCATCTTTTCCAATAGT 60
MECP2, methyl CpG-binding protein 2 gene; 3’UTR, 3’ untranslated region; bp, base pair; Tm, melting temperature; Ta, annealing
temperature; AS-PCR, allele-specific PCR.
Table 2
Coding region status and clinical presentation of the MECP2 3’UTR variant patients
Case 3’UTR variant Coding MECP2 mutation Parents Phenotype Reference
1 c.1461+9G>A negative NA Atypical RTT. Early epileptic encephalopathy, MR and
autism, had a period of regression. Presently with
autism.
@
2 c.1461+98insA negative father PMD delay, MR, autism and RTT-like stereotypies. @
3 c.2595G>A large deletion NA RTT congenital form. Developmental regression, with-
out purposeful use of hands, profound MR, never ac-
quired gait, scoliosis.
This study
4 c.9961C>G negative father MR, ataxia (independent gait and language), epilepsy, This study
c.9964delC mother stereotypies presently absent. [8]
MECP2, methyl CpG-binding protein 2 gene; 3’UTR, 3’ untranslated region; PMD, psychomotor development; MR, mental retardation;
RTT, Rett syndrome; NA, not available; @, http://mecp2.chw.edu.au.
3. Results
3.1. Bioinformatics
By computational analysis we identified several pu-
tative binding sites of trans-acting factors in the MECP2
3’UTR. We identified binding sites for the neuroon-
cological ventral antigen (NOVA), the arginine/serine-
rich splicing factors SRp40 and SRp55 and several
heterogeneous nuclear ribonucleoproteins (hnRNPs),
including the polypyrimidine tract-binding protein
(PTB); all these proteins are known to be involved in the
regulation of splicing and/or polyadenylation events.
Although biochemical evidence of binding needs to be
obtained, these findings reinforce the potential biolog-
ical relevance of this untranslated region and prompted
us to proceed to its genetic study.
3.2. MECP2 3’UTR variants
Variants in the 3’UTR of the MECP2 gene were
searched in 66 Portuguese patients with a clinical di-
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agnosis of RTT or mental retardation by Detection Of
Virtually All Mutations – SSCP (DOVAM-S) [18,23].
We identified 5 alterations in the 3’UTR of MECP2
gene: c.1461+9G>A, c.1461+98insA, c.2595G>A,
c.9961C>G and c.9964delC (NM 004992.2, Fig. 1 and
Table 2). None of the variants is localized in any of
the identified putative binding sites. The 1461+9G>A
and the 1461+98insA variants (identified by the di-
rect sequencing of exon/intron boundaries in our pre-
vious work) were already described in the literature
as polymorphisms (see MECP2 mutation database,
http://mecp2.chw.edu.au). The c.9964delC variant was
previously detected in a Portuguese control popula-
tion [8], and the c.2595G>A and c.9961C>G vari-
ants were identified for the first time in this study
and were not found in 218 X chromosomes of a Por-
tuguese control population. The variants c.9961C>G
and c.9964delC were both present in the same patient
(Table 2); the c.9961C>G variant was also present in
the unaffected father of the patient, hence this varia-
tion must not be a pathogenic mutation, and the variant
c.9964delC was present in the unaffected mother of the
patient who had an balanced X-chromosome inactiva-
tion pattern in her lymphocytes. We could not test the
c.2595G>A variant in the parents of the patient, since
their DNA was not available. However, this patient was
shown to have another causal mutation in trans (Ta-
ble 2), a large rearrangement of the MECP2 gene [22],
and so this variant is most likely not a pathogenic al-
teration. Since it is present only in this one patient, in
whom a severe clinical presentation was expected, we
cannot conclude whether this variant may behave as a
modifier of the phenotype.
4. Discussion
The long and highly conserved 3’UTR of the MECP2
gene suggested that mutations in this region could ex-
ist and underlie a percentage of the molecularly unex-
plained RTT cases; from 20% to 70% in classical and
atypical cases, respectively. The most interesting RTT
group to study was doubtlessly the one without MECP2
mutations in the coding region, although 3’UTR vari-
ants could also be modulators of the phenotype caused
by MECP2 coding region mutations. Our data sug-
gest that mutations in this region do not account for
a large proportion of the RTT cases without a genetic
explanation.
In a previous study, a 300-bp segment of the 3’UTR
around the 10 kb polyadenylation signal of the MECP2
gene was scanned for mutations in RTT patients and
no pathogenic variants were found [4]. Shibayama and
colleagues [23] studied a heterogeneous group of pa-
tients presenting schizophrenia, autism and other psy-
chiatric disorders and reported that 3’UTR variants in
the gene MECP2 seemed to be more frequent in autism
patients than in the general population. However, the
screening of the entire 3’UTR of MECP2 in an autis-
tic Portuguese population did not show any pathogenic
variant that could be responsible for the pathology, and
no heightened representation of 3’UTR sequence vari-
ants was found in this patient population as compared
to controls [8].
In our perspective, the contribution of the MECP2
3’UTR to RTT aetiology cannot be totally excluded
without studying a larger number of RTT patients of
different populations; analysis should focus in these
“blocks” of high conservation and with putative reg-
ulatory protein binding sites, for which we have es-
tablished a large-scale scanning method. Additional-
ly, other methods such as evaluation of mRNA levels
and stability and binding of specific proteins by RNA
protection assays may also be considered.
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